Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor ...

JNJ-2113 is under clinical development by Johnson & Johnson and currently in Phase III for Psoriatic Arthritis.

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for ...

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Chronic kidney disease is not uncommon among patients with PsA, with risk factors including diabetes and NSAID use, while ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

A study of biologic-naive patients with psoriasis or PsA found that IL-17, IL-12/23, and IL-23 inhibitors have comparable cardiovascular and thrombotic risk profiles as TNF inhibitors.

Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Introduction: The relationship between the phenotype and treatment of psoriatic arthritis (PsA) and the increased prevalence of cardiovascular comorbidities is not well studied. Objective: To assess ...